To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
180
Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
Amlodipine 10mg+Valsartan 160mg
Valsartan 160mg+Atorvastatin 40mg
Asan Medical Center
Seoul, South Korea
Change in siSBP
Change in siSBP from baseline after 8 weeks of study treatment
Time frame: baseline and 8 weeks
Change in LDL-C
Change in LDL-C from baseline after 8 weeks of study treatment
Time frame: baseline and 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.